Introduction
============

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy, and its incidence and severity have been suggested to increase with age.[@b1-cia-13-117]--[@b3-cia-13-117] Based on the World Health Organization, most developed countries in the world have accepted the age of "65" years as "elderly", but many studies consider the age of "60" as elderly in developing countries.[@b4-cia-13-117] Lam and Thurston's study indicates that there were significantly more CTS patients aged \>55 years than in the general population.[@b3-cia-13-117] In a similar pattern, Vessey et al reported a doubling in the rate of CTS after the age of 50 years.[@b5-cia-13-117] Another study by Bland and Rudolfer showed a bimodal age distribution with the first peak between the ages of 50 and 54 years and a second peak within 75--84 years.[@b1-cia-13-117] Since there is no definite cutoff age for such kind of effect in the case of CTS patients, the cutoff age for elderly discrimination and intervention has significant variance in the literature.[@b1-cia-13-117],[@b2-cia-13-117],[@b6-cia-13-117]--[@b9-cia-13-117]

The elderly have a higher prevalence of severe CTS, introduced with the presence of thenar wasting and a severe nerve conduction deficit.[@b1-cia-13-117],[@b9-cia-13-117]--[@b13-cia-13-117] Blumenthal et al have postulated that there were no age differences in CTS symptoms, hand function, the presence of autonomic symptoms, or the presence of Tinel's or Phalen's sign,[@b7-cia-13-117] but some other studies reported significant differences.[@b8-cia-13-117],[@b9-cia-13-117],[@b13-cia-13-117] Aging per se causes changes in peripheral nerves' structural, physiological, and functional characteristics.[@b14-cia-13-117],[@b15-cia-13-117] If CTS is left untreated, it can lead to long-term disability secondary to permanent median nerve damage.[@b16-cia-13-117]--[@b18-cia-13-117] To avoid this permanent sequela, the elderly should be considered as a high-risk group even in the absence of firm clinical evidence.

Elderly persons are also more likely to have coexisting comorbidities such as cardiac disease, hypertension, diabetes mellitus, hypothyroidism, and cervical spondylosis leading to cervical radiculopathy and/or myelopathy, etc. Polypharmacy for managing such multiple comorbidities complicates the clinical picture and may add to physiological changes in the nerve.[@b19-cia-13-117] Thus, in these patients, it is of particular importance to optimize treatment protocols and, in the case of carpal tunnel injection, to select the optimal dose of medication while minimizing adverse effects. However, the optimal dose is still not defined entirely in younger patients.

Ultrasound-guided hydrodissection is a recently developed treatment method in CTS described by Malone et al.[@b20-cia-13-117] To the best of our knowledge, there is no study comparing different doses of corticosteroids in elderly CTS patients using this technique. Thus, we sought to run this randomized, controlled trial.

Methods
=======

Setting and subjects
--------------------

The trial design was a prospective, triple-blind, randomized, controlled study in patients aged \>50 years diagnosed with CTS and referred to the Physical Medicine and Rehabilitation Clinic of University Hospital, Tehran, Iran, during the period 2014--2016. Although the age of 60 years has been adjudged as elderly in Iran, since epidemiologic studies reported growing CTS prevalence after the age of 50 years with suggested bimodal peak ages between 50--54 and 75--84 years and the need for early intervention in elderly; we recruited patients aged \>50 years.[@b1-cia-13-117],[@b3-cia-13-117]--[@b5-cia-13-117]

Only one physician screened and examined patients for eligibility. Our inclusion criteria were clinical diagnosis of CTS and electrodiagnostic (EDX) confirmation of moderate CTS: for clinical diagnosis, our physician examined all patients based on the American Academy of Orthopaedic Surgeons Clinical Practice Guideline recommendations.[@b21-cia-13-117],[@b22-cia-13-117] The examiner included a detailed history, personal characteristics, pace activities, and comorbidities of the patients. Accordingly, he conducted a standard sensory examination, manual muscle testing of the upper extremity, and provocative tests, eg, Phalen and compression test and discriminatory tests such as Spurling test for alternative diagnoses. In the EDX part, nerve conduction studies (NCSs) were performed by just one physician with \>10 years of experience, based on the guidelines of the American Association of Neuromuscular and Electrodiagnostic Medicine for suspected CTS.[@b23-cia-13-117] The reference values of CTS outlined by Dumitru et al were used.[@b24-cia-13-117] Only the dominant hand in patients with bilateral CTS was chosen, in order to optimize patients' function.

In order to screen for pure moderate severity in CTS patients, minimizing possible adverse effects of steroids and eliminating confounding factors as much as possible, the following were set as exclusion criteria: 1) severe weakness, requiring carpal tunnel release; 2) a previous history of CTS treatment or injection; 3) corticosteroid or triamcinolone allergy or contraindication; 4) diabetes mellitus, rheumatoid arthritis, thyroid dysfunction, or any severe heart disease, including life-threatening arrhythmia;[@b25-cia-13-117] 5) the presence of neurologic disorders such as polyneuropathy, proximal median or ulnar neuropathy, plexopathy, mononeuritis multiplex, and cervical radiculopathy, applying EDX tests.

Measurements
------------

Demographic data, including age, gender, and medication profile, were recorded. Forearm length, hand length, and wrist diameter were measured, by using a caliper; wrist circumference was measured by using a tape measure. Pain severity and hand force were evaluated at baseline by visual analog scale (VAS) and hand dynamometer, respectively. NCS parameters were evaluated to confirm the diagnosis of moderate CTS as described above. Clinical severity of symptoms was evaluated by using a validated 19-item Boston Carpal Tunnel Questionnaire (BCTQ), including 11-item Symptom Severity Scale and 8-item Functional Status Scale. BCTQ scoring was based on a 1--5 grading scale for each item, meaning "normal" to "very severely affected," respectively. Median nerve inlet cross-sectional area was used as the sonographic outcome measure, being the most sensitive and specific parameter for diagnosing CTS sonographically.[@b26-cia-13-117]--[@b28-cia-13-117] Median nerve distal motor latency (median DML) and median nerve sensory nerve action potential were recorded as the EDX outcome measures. All data were recorded at baseline, 2 weeks, 3 months, and 6 months after injection. Patients were also asked about the possible adverse effects at each follow-up visit.

Design
------

Recruited subjects who met inclusion and exclusion criteria were randomized to one of three groups using a computer-generalized randomization list, and the labeling process was performed by a third person not involved in the project, followed by baseline assessments.

Each patient received a unique code, indicating their assigned group. A study nurse was the only investigator aware of the code, and she prepared the study injection medication out of the sight of the injector and patient in an opaque syringe (covered with white opaque paper) based on the group allocation, immediately before the injection procedure. All syringes contained a total of 3 mL of injectate for the hydrodissection. Group I received 80 mg triamcinolone (2 mL) and 1 mL of 2% lidocaine; Group II received 40 mg triamcinolone (1 mL), 1 mL of 2% lidocaine, and 1 mL normal saline; Group III received 1 mL of 2% lidocaine and 2 mL normal saline.[@b20-cia-13-117] However, lidocaine per se has been suggested to provide some beneficial results because of its anti-inflammatory effects,[@b29-cia-13-117]--[@b33-cia-13-117] and steroids are often mixed with this local anesthetic to reduce pain during injection in order to make patients tolerant to dissection's pain during the injection and after discharge. We also tried to eliminate such probable confounding effects by unifying its dosage across the study groups. In all the groups, a wrist splint for support was administered immediately after the injection.

Atroshi et al evaluated the effectiveness of methylprednisolone,[@b34-cia-13-117] but we tried triamcinolone because it was more accessible in our market at that time; however, it is less soluble and has longer lasting effects, less rapid effect, and more subcutaneous fat atrophy.[@b35-cia-13-117] We did the injection carefully in order to not pass the injectate further than the proximal edge of the flexor retinaculum, applying pressure in the most proximal part of the sonography probe during injection and closing the trajectory at the time of withdrawal and for a while after that.

The Esaote ultrasound system (MyLab™-25; Esaote, Genoa, Italy) with 10--18 MHz multidimensional linear-array transducer was employed in the study. Study subjects were positioned supine, with the forearm in relaxed supination and the wrist in slight dorsiflexion. The ultrasound probe was placed perpendicular to the distal wrist crease, parallel to the anatomical sagittal axis. The proximal border was placed on the radiolunate joint at the volar aspect of the forearm. Then, the distal border was set about 1 cm distal to the distal wrist crease, at the distal end of the capitate bone. After adjusting the probe, identifying the maximal nerve diameter ([Figure 1](#f1-cia-13-117){ref-type="fig"}), and skin preparation, a 26-gauge needle was introduced into the palmar surface of the hand applying in-plane approach. After passage beneath the distal edge of the flexor retinaculum, the drug was injected gradually, and the needle was advanced proximally toward the level of the radioulnar joint, dissecting the flexor retinaculum away from the median nerve via gradual drug infiltration, and trying not to pass the proximal part of the flexor retinaculum by advancing the needle gradually and compressing the proximal part of the probe. At the end of the injection, prior to withdrawing the needle, the physician covered the skin over the needle entry site with sterile gauze, closing the trajectory and remaining blinded, in case of medication leakage.[@b20-cia-13-117],[@b25-cia-13-117]

Ethical issues and registration
-------------------------------

The trial was performed in full compliance with the Declaration of Helsinki after acquiring approval from the Ethics Review Board of the Baqiyatallah University of Medical Sciences (No 34-13). The trial was registered in IRCT.ir (Identifier Number: IRCT2014020416485N1). All subjects were informed of the study objectives, options for CTS treatment, and potential side effects of hydrodissection with local steroid injection, including hypopigmentation, subcutaneous atrophy, and possible median nerve injury.[@b20-cia-13-117],[@b25-cia-13-117] Written informed consent was received from all the patients.

Sample size
-----------

Considering a total success rate of 70% for local steroid injection, based on a review by Jeremy Bland,[@b36-cia-13-117] with an absolute precision of 0.2, the final sample size was estimated to be at least 21 subjects per group. The power and the significance level were set at 0.8 and 0.05, respectively. Jeremy Bland considered the last two responses from worth/no effect/slightly better/much better/cured, as equivalent to success after CTS treatment.[@b36-cia-13-117]

Statistical analysis
--------------------

All statistical analyses were performed by using IBM SPSS Statistics, Version 19.0 (SPSS Inc., Chicago, IL, USA), and the patients were included in the analysis according to the intention-to-treat principle. Descriptive statistics were used to summarize the data, representing medians and ranges with nonparametric data, while the mean and standard deviation were employed using parametric data. Distribution of data was tested using the Kolmogorov--Smirnov test. An α\<0.05 was considered significant. Repeated-measures analysis of variance (ANOVA), followed by Tukey's post hoc testing and its nonparametric equivalent, Friedman, was used to compare quantitative variables among the three treatment groups before the study intervention and at the follow-up visits. To compare the demographic variables, a one-way ANOVA test was applied.

Results
=======

A total of 161 consecutive patients were screened during the study period, of whom 18 did not meet the inclusion criteria, 27 declined to participate, and 14 met the exclusion criteria. The remaining 102 patients were randomly allocated to three intervention groups. Of these, 94 patients completed the entire study course and were analyzed. Two subjects in Group I, three subjects in Group II, and three subjects in Group III withdrew during the course of the study. These dropouts did not wish to explain the reason for their withdrawal during a subsequent telephone follow-up. However, they denied any side effects of the injection and any complication. [Figure 2](#f2-cia-13-117){ref-type="fig"} illustrates the study flow chart.

[Table 1](#t1-cia-13-117){ref-type="table"} presents the demographic data of the participants. There were no statistical differences between the groups. [Table 2](#t2-cia-13-117){ref-type="table"} presents descriptive data on primary outcome measures at different follow-up points, together with the within-group effects. Variables with a normal distribution (*p*-value \>0.05) were marked with an asterisk. Although we have not matched the groups based on the baseline primary outcome measurements, no significant differences between groups' baseline primary outcomes were detected, except for the VAS measure, in which post hoc analysis revealed a significant difference between baseline VAS scores in Groups I and III. [Table 3](#t3-cia-13-117){ref-type="table"} presents the normal distribution of the primary outcome measures. In all the three groups, there were significant improvements in symptom score, sonographic measures, and electrophysiologic measures with the sole exception of the median DML in Group III, which decreased over the follow-up period, but not to a statistically significant level. A Scheffe post hoc analysis revealed differences in median DML between Groups II and III, with higher values in Group II (*p*-value =0.049).

Discussion
==========

In this study, the efficacy of hydrodissection using two different doses of steroid and one dose of lidocaine was compared in elderly patients with moderate CTS. The results showed a significant within-group trend in a symptomatic improvement in almost all clinical, EDX, and ultrasonographic outcomes, with no statistically significant difference between groups. The only exception was median DML, in which post hoc analysis revealed a borderline difference between Groups II and III, with higher values for the former, making us suggest further investigations into this topic.

The high prevalence of CTS, which has been suggested to increase with age, potential for functional impairment with the associated impact on the quality of life due to permanent axonal loss, and the cost of surgery in severe cases highlight the need for proper management, especially in the elderly.[@b37-cia-13-117]--[@b39-cia-13-117] Although, Lam and Thurston and Vessey et al's studies have suggested a significant higher prevalence of CTS over 55 and 50 years, respectively, and Bland and Rudolfer reported a bimodal peak prevalence for CTS between the ages of 50--54 and 75--84 years, the controversy about the cutoff age has not yet been resolved.[@b1-cia-13-117],[@b3-cia-13-117],[@b5-cia-13-117] Therefore, cutoff age for elderly discrimination has significant variance in the literature. A prospective study of Porter et al found that the symptoms and function improvement decreases after operation in the elderly; they chose a cutoff age of 60 years without any explanation.[@b9-cia-13-117] Stone et al showed that, even with the cutoff age of 80 years, the functional outcome and patients' satisfaction rate after decompression were similar to the younger control group (\<80 years old), though the elderly are more likely to have thenar muscle atrophy and a severe nerve conduction deficit.[@b13-cia-13-117] In another study by Hobby et al using five age-groups, patients aged between 60--69 were similar to younger patients' symptoms and functions evaluated with BCTQ score, post-operatively. However, some evidence of poorer outcomes in patients aged \>70 years was also concluded; the authors finally declared that outcomes are less predictable in patients aged \>70 years.[@b8-cia-13-117] However, no study evaluated the effect of age on postinjection outcomes in elderly patients with CTS.

Furthermore, elderly patients usually have more comorbidities, such as cardiac disease, diabetes mellitus, and hypertension, hence they are affected by higher complication rates when receiving surgery or higher doses of steroids. Recent meta-analyses have shown that corticosteroid injections diminish symptom severity and improve function in comparison with placebo.[@b40-cia-13-117],[@b41-cia-13-117] However, steroids are often mixed with local anesthetics to reduce pain postinjection, among which lidocaine is the most commonly used agent.[@b33-cia-13-117] Adverse effects of steroids on diabetes mellitus and hypertension must be taken into consideration when electing to treat patients with steroids. Consequently, nonsteroid injections in elderly patients may be a reasonable choice due to less adverse effects. Lidocaine produces local anesthesia through selective blockade of Aδ and C nerve fibers. It also produces vasodilatation, modulated by endothelial cell secreted nitrous oxide, through simultaneous blockade of sodium channels.[@b42-cia-13-117] A systematic review suggested that lidocaine has a potential role as an anti-inflammatory agent.[@b29-cia-13-117] It has been postulated that the inhibition of nuclear factor-κB through the phosphorylation of p38 mitogen active protein kinase by lidocaine can account for the anti-inflammatory effects,[@b30-cia-13-117]--[@b32-cia-13-117] and this could be a potential explanation for the results observed in Group III, where only lidocaine, and no steroid, was administered. However, without a sham group, it could not concluded as a real effect to differentiate it from placebo effect.

The pathophysiology of CTS is not completely understood. Increased pressure, either by adhesion caused by noninflammatory fibrosis of subsynovial connective tissue surrounding the median nerve[@b43-cia-13-117] or by a volume increase within the carpal tunnel, as well as flexor tendon synovial connective tissue adhesion around the median nerve, is a possible etiology.[@b44-cia-13-117] Hydrodissection itself may address the adhesions, separating the nerve from the surrounding tissues. To our knowledge, there are no prior studies comparing different corticosteroid doses in combination with hydrodissection in elderly patients. Dernek et al[@b45-cia-13-117] studied 67 CTS patients diagnosed on the basis of physical examination and NCSs. Some received a blend of 0.5 mL normal saline solution and 0.5 mL lidocaine, while the rest received 1 mL betamethasone dipropionate. Results showed that there were no significant differences between groups at baseline and 1-, 3-, and 6-month postinjection follow-ups in VAS or Quick Disabilities of the Arm, Shoulder, and Hand scores. Consequently, the authors suggested lidocaine injection was an excellent alternative to corticosteroid injection, without potential side effects.[@b45-cia-13-117] Another randomized, placebo-controlled trial by Karadas et al in CTS patients was conducted in 2012. They enrolled 57 CTS patients, who were assigned to one of three groups: group 1 received 1 mL 0.09% normal saline, group 2 received 40 mg triamcinolone acetonide, and group 3 received 4 mL 1% procaine HCl. The same degree of improvement was observed in groups 2 and 3, but not in group 1 at the 2- and 6-month postinjection follow-ups.[@b46-cia-13-117] Lack of blinded design and applying a different volume of injection in different groups were limitations of that study, however. We chose not to have a placebo group in our study, to avoid pain related to high-volume injections, with a potential detrimental impact on patient recruitment and preventing study approval by our ethics committee.

Some studies suggest that local anesthetic should be used in CTS patients in whom steroids are contraindicated, eg, those with severe diabetes mellitus and hypertension.[@b46-cia-13-117] Vahi et al pointed out in their study that postoperative complications were more common in those with multiple preoperative steroid injections.[@b47-cia-13-117] However, the Bland and Ashworth study refuted that the prior local steroid injection can prejudice the outcome of surgery.[@b48-cia-13-117] Consequently, in cases where surgical intervention may be indicated or has to be delayed, lidocaine injection might be more appropriate than steroid injection, especially in the elderly.

Strengths of this study included the use of a gold standard approach to the clinical diagnosis; the use of outcome measures such as the BCTQ, NCSs, and ultrasound parameters; and the inclusion of relatively long-term follow-up. Further methodological strengths of the study are that outcome was assessed prospectively in a consecutive series of patients with almost complete follow-up. Our study did not compare the results of the elderly with younger patients, nor include a true placebo group and an untreated/sham control group. Another major limitation of our study was the restricted follow-up time of about 6 months, rather than 12 months. We also did not match the groups regarding baseline measurements, and the base line analysis showed up with a significant difference for VAS between Groups I and III in post hoc analysis, which may be a source of error in the final conclusion, though other measures have no significant difference at baseline.

Conclusion
==========

Ultrasound-guided hydrodissection of the median nerve with either lidocaine and steroid or lidocaine alone may be efficacious and safe in the treatment of moderate CTS in elderly patients, especially in those with severe comorbidities where steroids can not be used. However, further investigation, considering baseline measures matching and comparing to a sham placebo group, is needed in order for definitive recommendations to be made.
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![Sonography, injection, and blinding for injector.\
**Note:** The syringe was covered by a sterile opaque white paper (left picture); flexor retinaculum (FR), median nerve (MN), and the injectate (INJ) for dissection are shown in the middle picture; covering the needle at the time of withdrawal (right picture).\
**Abbreviations:** FT, flexor tendon; CB, carpal bone.](cia-13-117Fig1){#f1-cia-13-117}

![Study flowchart.\
**Note:** Group I received 80 mg triamcinolone (2 mL) and 1 mL of 2% lidocaine; Group II received 40 mg triamcinolone (1 mL), 1 mL of 2% lidocaine, and 1 mL normal saline; Group III received 1 mL of 2% lidocaine and 2 mL normal saline.](cia-13-117Fig2){#f2-cia-13-117}

###### 

Patients' demographics

  Variables                              Group I (n=32)   Group II (n=32)   Group III (n=30)   *p*-value
  -------------------------------------- ---------------- ----------------- ------------------ -----------
  Gender (male/female)                   10/22            4/28              3/27               0.057
  Age (years) (mean ± SD)                66.1±13.4        66±10             63.4±10.7          0.645
  Affected hand (right/left)             18/14            16/16             19/11              0.57
  Affected hand (dominant/nondominant)   19/13            16/16             19/11              0.549
  Wrist circumstance (cm) (mean ± SD)    17.2±1.3         17±1              17±1               0.726
  Wrist diameter (mm) (mean ± SD)        59.8±3.9         59.7±4.2          59.8±3.7           0.991
  Hand length (cm) (mean ± SD)           17.5±1.3         17.5±1.1          17.3±0.8           0.801
  Forearm length (cm) (mean ± SD)        23.1±1.5         23.3±1.3          23±1.5             0.618
  Hand power (kg) (mean ± SD)            20.1±8.1         23.6±8.4          19.1±7.5           0.06

**Note:** Group I received 80 mg triamcinolone (2 mL) and 1 mL of 2% lidocaine; Group II received 40 mg triamcinolone (1 mL), 1 mL of 2% lidocaine, and 1 mL normal saline; Group III received 1 mL of 2% lidocaine and 2 mL normal saline.

**Abbreviation:** SD, standard deviation.

###### 

Outcome measures at baseline and follow-up

  Primary outcome measure   Treatment group                                          Baseline                                                 2-week follow-up                                         3-month follow-up                                        6-month follow-up                                        Friedman test
  ------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ---------------
  VAS (mean ± SD)           Group I (n=32)                                           7.29±2.05[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.24±2.09[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.15±2.21[\*](#tfn3-cia-13-117){ref-type="table-fn"}     2.43±1.93[\*](#tfn3-cia-13-117){ref-type="table-fn"}     \<0.001
  Group II (n=32)           6.22±2.74[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.81±2.39[\*](#tfn3-cia-13-117){ref-type="table-fn"}     3.23±2.03[\*](#tfn3-cia-13-117){ref-type="table-fn"}     2±1.44                                                   \<0.001                                                  
  Group III (n=30)          5.8±1.88[\*](#tfn3-cia-13-117){ref-type="table-fn"}      4.2±1.75[\*](#tfn3-cia-13-117){ref-type="table-fn"}      3.19±2.12[\*](#tfn3-cia-13-117){ref-type="table-fn"}     2.75±2.56                                                \<0.001                                                  
  Median DML (mean ± SD)    Group I (n=32)                                           5.08±1.35[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.70±1.2[\*](#tfn3-cia-13-117){ref-type="table-fn"}      4.55±1.12[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.32±0.66[\*](#tfn3-cia-13-117){ref-type="table-fn"}     0.001
  Group II (n=32)           5.15±1.23                                                5.00±1.23[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.80±1.23[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.65±0.8[\*](#tfn3-cia-13-117){ref-type="table-fn"}      \<0.001                                                  
  Group III (n=30)          4.69±1.51[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.50±1.32[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.45±1.19[\*](#tfn3-cia-13-117){ref-type="table-fn"}     4.16±0.7[\*](#tfn3-cia-13-117){ref-type="table-fn"}      **0.887**                                                
  Median SNAP (mean ± SD)   Group I (n=32)                                           4.05±1.55                                                3.73±1.5                                                 3.80±1.39                                                4.04±0.75[\*](#tfn3-cia-13-117){ref-type="table-fn"}     0.01
  Group II (n=32)           3.28±2.2                                                 3.24±1.94                                                3.71±1.68                                                4.05±1.51[\*](#tfn3-cia-13-117){ref-type="table-fn"}     0.025                                                    
  Group III (n=30)          3.90±1.15                                                3.80±1.18[\*](#tfn3-cia-13-117){ref-type="table-fn"}     3.96±0.93[\*](#tfn3-cia-13-117){ref-type="table-fn"}     3.86±0.36[\*](#tfn3-cia-13-117){ref-type="table-fn"}     0.037                                                    
  Inlet CSA (mean ± SD)     Group I (n=32)                                           11.73±2.53[\*](#tfn3-cia-13-117){ref-type="table-fn"}    10.77±2.18[\*](#tfn3-cia-13-117){ref-type="table-fn"}    10.78±2.39[\*](#tfn3-cia-13-117){ref-type="table-fn"}    10.45±2.37[\*](#tfn3-cia-13-117){ref-type="table-fn"}    0.002
  Group II (n=32)           12.23±2.49[\*](#tfn3-cia-13-117){ref-type="table-fn"}    11.55±2.4[\*](#tfn3-cia-13-117){ref-type="table-fn"}     11.26±2.19[\*](#tfn3-cia-13-117){ref-type="table-fn"}    10.26±2.34[\*](#tfn3-cia-13-117){ref-type="table-fn"}    \<0.001                                                  
  Group III (n=30)          12.09±3.96[\*](#tfn3-cia-13-117){ref-type="table-fn"}    11.23±2.72[\*](#tfn3-cia-13-117){ref-type="table-fn"}    11.37±1.97[\*](#tfn3-cia-13-117){ref-type="table-fn"}    10.76±2.05[\*](#tfn3-cia-13-117){ref-type="table-fn"}    0.007                                                    
  Boston (mean ± SD)        Group I (n=32)                                           55.81±15.04[\*](#tfn3-cia-13-117){ref-type="table-fn"}   41.95±11.26[\*](#tfn3-cia-13-117){ref-type="table-fn"}   40.43±12.14[\*](#tfn3-cia-13-117){ref-type="table-fn"}   34.06±10.25[\*](#tfn3-cia-13-117){ref-type="table-fn"}   0.001
  Group II (n=32)           47.70±11.70[\*](#tfn3-cia-13-117){ref-type="table-fn"}   44.94±9.70[\*](#tfn3-cia-13-117){ref-type="table-fn"}    43.41±10.97[\*](#tfn3-cia-13-117){ref-type="table-fn"}   38.67±11.21[\*](#tfn3-cia-13-117){ref-type="table-fn"}   \<0.001                                                  
  Group III (n=30)          45.22±13.84[\*](#tfn3-cia-13-117){ref-type="table-fn"}   40.45±11.08[\*](#tfn3-cia-13-117){ref-type="table-fn"}   41.27±12.65[\*](#tfn3-cia-13-117){ref-type="table-fn"}   36.94±13.04[\*](#tfn3-cia-13-117){ref-type="table-fn"}   0.018                                                    

**Notes:**

Test distribution is normal. Group I received 80 mg triamcinolone (2 mL) and 1 mL of 2% lidocaine; Group II received 40 mg triamcinolone (1 mL), 1 mL of 2% lidocaine, and 1 mL normal saline; Group III received 1 mL of 2% lidocaine and 2 mL normal saline. Bold variable represents a significant difference between groups after treatment.

**Abbreviations:** CSA, cross-sectional area; DML, distal motor latency; VAS, visual analog scale; SD, standard deviation; SNAP, sensory nerve action potential.

###### 

Between-group analyses

  Primary outcome   Repeated measurement ANOVA (between group)
  ----------------- --------------------------------------------
  VAS               0.399
  Median DML        **0.03**
  Inlet CSA         0.512
  Boston            0.756

**Note:** Bold variable represents a significant difference between groups after treatment.

**Abbreviations:** ANOVA, analysis of variance; CSA, cross-sectional area; DML, distal motor latency; VAS, visual analog scale.
